Michael Berry
Chief Tech/Sci/R&D Officer bij EVEREST MEDICINES LIMITED
Profiel
Michael Berry is currently the Chief Technology Officer at Everest Medicines Ltd.
He previously worked as the Senior Director of Bioprocess Development at Portola Pharmaceuticals, Director at ARCA biopharma, Director of Manufacturing Sciences & Technology at Novartis Vaccines & Diagnostics SL, and Vice President at Dynavax Technologies Corp.
He is also the Chief Technical Operations Officer at Clover Biopharmaceuticals Ltd.
Berry received his undergraduate degree from De Montfort University, his graduate degree from The University of Manchester, and his doctorate from the University of Manitoba.
Actieve functies van Michael Berry
| Bedrijven | Functie | Begin |
|---|---|---|
| EVEREST MEDICINES LIMITED | Chief Tech/Sci/R&D Officer | 15-06-2023 |
Eerdere bekende functies van Michael Berry
| Bedrijven | Functie | Einde |
|---|---|---|
| DYNAVAX TECHNOLOGIES CORPORATION | Corporate Officer/Principal | 01-08-2017 |
| PORTOLA PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01-02-2015 |
| Novartis Vaccines & Diagnostics SL | Corporate Officer/Principal | 01-09-2013 |
| ARCA BIOPHARMA, INC. | Director/Board Member | 01-05-2009 |
| CLOVER BIOPHARMACEUTICALS, LTD. | Chief Tech/Sci/R&D Officer | - |
Opleiding van Michael Berry
| The University of Manchester | Graduate Degree |
| University of Manitoba | Doctorate Degree |
| De Montfort University | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 4 |
|---|---|
| DYNAVAX TECHNOLOGIES CORPORATION | Health Technology |
| ARCA BIOPHARMA, INC. | Health Technology |
| EVEREST MEDICINES LIMITED | Health Technology |
| CLOVER BIOPHARMACEUTICALS, LTD. | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
Portola Pharmaceuticals LLC
 Portola Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Portola Pharmaceuticals, Inc. engaged in the development and commercialization of novel therapeutics in the areas of thrombosis, other hematologic disorders, and inflammation. It offers Andexxa and Bevyxxa medicines. The company was founded by Charles J. Homcy and David R. Philips on September 2, 2003 and is headquartered in South San Francisco, CA. | Health Technology |
| Novartis Vaccines & Diagnostics SL |
